Lyka Labs Ltd.

₹59.87

-1.8 (-3%)

LYKALABS Share Price

Pharmaceuticals & Biotechnology

As on July 29, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 216 Cr

P/E Ratio-21.3

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	62.28	Bearish
10-DMA	65.05	Bearish
20-DMA	67.72	Bearish
50-DMA	66.45	Bearish
100-DMA	61.83	Bearish
200-DMA	71.03	Bearish

Historical Performance

1 Year

-48.1%

3 Years

-46.1%

5 Years

-21.1%

10 Years

-16%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	1,284	1,385	1,112	931	1,941
Total Expenditure	1,319	1,206	955	762	929
Other Income	35	22	15	34	21
Operating Profit	---	202	172	202	1,032
Interest	33	23	49	119	201
Depreciation	85	68	128	141	173
Profit Before Tax	-118	111	-9	-132	592
Consolidated Net Profit	-100	80	-25	-132	390
Adjusted EPS	-3	2	-1	-4	14

Compounded Sales Growth

10 Years:-0.3

5 Years:8.3

3 Years:6.7

TTM:-1.5

Compounded Profit Growth

10 Years:-1.2

5 Years:-2.8

3 Years:-5.4

TTM:-15.4

Stock Price CAGR

10 Years:-1.7

5 Years:-5.5

3 Years:-18.6

TTM:-47.4

Return on Equity

10 Years:-2.5

5 Years:13.6

3 Years:-0.8

last year:-2.8

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	357	357	331	307	287
Total Reserves	562	686	260	-27	-154
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	298	260	508	733	728
Other Current Liabilities	168	153	124	143	662
Short Term Borrowings	191	148	116	76	201
Total Liabilities	1,745	1,762	1,569	1,515	1,856
Capital Work in Progress	19	2	220	151	162
Long Term Loans & Advances	223	224	254	230	217
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	64	41	48	25	56
Total Current Assets	633	674	507	442	522
Total Assets	1,745	1,762	1,569	1,515	1,856
Adjusted Book Value	26	29	18	9	5

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of -21.3, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -18.9%, indicating poor shareholder returns.
The stock carries a beta of 1.1, indicating volatility broadly in line with the market.
In the last financial year, the company reported a negative or negligible EBITDA of ₹0 million, indicating weak operating profitability.
In the previous financial year, the company generated revenue of ₹1284 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 526237.1

No. of Shares: 8790 (Approx)

Performance:-47.4%

-473762.9

NIFTY Performance: -2.4%

1 day Top Gainers